About MS  > MS news and research  > Drugs  > MN-166
About MS

What is MS?

MS symptoms

Managing your MS

Effects of MS

MS news and research

Alternative medicine

Bacteria and viruses

Biomarkers and microRNA

Botox

Brain inflammation, lesions & 'black holes'

Brain iron deposits

Cancer and MS

CCSVI

Cognition

Diet

Drugs

Ampyra (Fampyra)

ATL1102

ATX-MS-1467

Aubagio

Cannabis and cannabinoids

Copaxone and glatiramer acetate

Cyclophosphamide

Emerging therapies

Gilenya

Low dose naltrexone

Lemtrada (alemtuzumab)

MIS416

MN-166 (ibudilast)

Nerventra® (laquinimod)

Plegridy (peginterferon beta-1a)

Rebif

Rituximab (rituxan)

RPC1063

Sativex

Statins

Tecfidera

Trimesta (oral estriol)

Tysabri

Zenapax (daclizumab)

Endo-parasites and helpful organisms

Environmental factors

Ethnic groups, geographical regions and MS

Exercise

Gender and MS

Genetics

Hormones

Immune cells

Lipids

Medical imaging

MS Symptoms research

Multiple Sclerosis (etiology)

Myelin

Nerves, brain cells and spinal cord

Paediatric MS

Pain

Potential viral causes

Quality of life

Retroviruses

Sex and MS

Stem cells

Stress

Technology

Types of MS

Vaccinations

Vitamin D

World MS Day

News and research archive

Other support

Donate with JustGiving

Latest Tweets

MN-166 (ibudilast)

Neurons

 

 

 

 

 

 

 

Ibudilast treatment for progressive multiple sclerosis to be tested in phase II trials(19/03/14)

The University of Virginia (UVa) Medical Center has joined 27 other hospitals around the country in conducting a series of neurological clinical trials. Specifically, UVa recently enrolled in NeuroNEXT (Network for Excellence in Neuroscience Clinical Trials), which is sponsored by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health.

UVa is currently recruiting participants for its Phase 2 Clinical Trial to evaluate the safety, tolerability, and activity of ibudilast in patients with primary- or secondary-progressive multiple sclerosis; they hope to recruit 250 male and female subjects ages 21 to 65 years old who have no prior treatment with long-term multiple sclerosis disease modifying therapy or who are receiving glatiramer acetate or interferon beta treatment. Ibudiblast will be administered in conjuction with glatiramer or interferon beta treatment and compared to a placebo.

Participants will receive placebo or 100 mg/day ibudilast for 96 weeks. Primary outcome measures include brain atrophy over 96 weeks and treatment-emergent adverse events over 36 months. Secondary outcome measures include inflammatory, disability, and quality of life statuses, as well as cognitive impairment and neuropathic pain. The study is projected to end in March 2017 with a primary completion date in December 2016.

Ibudilast is special because it is designed to treat patients with progressive multiple sclerosis, and according to Dr. Myla D. Goldman at UVa’s James Q. Miller Multiple Sclerosis Clinic, current medications have failed to stop or slow progressive multiple sclerosis. Consequently, patients have little relief of their symptoms that gradually worsen over time.

Source: BioNews Texas (19/03/14)